SecBot SecBot
8-K ·Filed Sep 16, 2026

KTTA

Pasithea Therapeutics Corp.
NEUTRAL
Impact 3/10
Horizonimmediate Processed1mo ago SEC0001213900-26-100515
8-K context-dependent: Items 8.01
Actionable Insight • Neutral

Warrant holders must exercise before September 17, 2026, or lose all value. The expiration removes potential future dilution from warrant exercises, but the company's common stock and operations are unaffected. Monitor for any subsequent filings regarding the warrant exercise results.

DirectionNeutral
Confidencehigh
Horizonimmediate
Latest settled — T+20d
KTTA ▼ -19.06% at T+20d
NEUTRAL call -19.06% · α vs SPY -20.27% · entry $0.5067 → $0.4101
Next anchor: T+60d in 6w
Latest observation: T+26 -16.01% FF3 residual α
Entry = T+0 close
Sep 16, 2026
via day close
T+1d
+3.35%
call +3.35% · α +3.47%
$0.5237
settled 6w ago
T+5d
+1.38%
call +1.38% · α +0.78%
$0.5137
settled 5w ago
T+20d
-19.06%
call -19.06% · α -20.27%
$0.4101
settled 13d ago
T+60d
Pending
in 6w

Price Chart

Loading chart...

Executive Summary

Pasithea Therapeutics announced that its publicly traded warrants (KTTAW) will expire on September 17, 2026, and will cease trading on Nasdaq. A Form 25 will be filed to delist and deregister the warrants. The common stock (KTTA) will continue trading normally.

Key Facts

  • Warrants (KTTAW) expire on September 17, 2026, per the Warrant Agency Agreement with VStock Transfer, LLC.
  • Any warrants not exercised before expiration will become worthless.
  • A Form 25 will be filed to delist and deregister the warrants from Nasdaq and Section 12(b) of the Exchange Act.
  • Common stock (KTTA) will continue trading on Nasdaq unaffected.

Financial Impact

No financial figures provided. Warrants expiring worthless for holders who do not exercise; no cash impact on the company.

Risk Factors

  • Warrant holders who fail to exercise before expiration will receive no value.
  • Delisting of warrants reduces liquidity for any remaining warrant positions.

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001213900-26-100515
Document: 0001213900-26-100515-index-headers.html0001213900-26-100515
Document: 0001213900-26-100515-index.html0001213900-26-100515
Document: 0001213900-26-100515.txt0001213900-26-100515
2 reports for KTTA
Performance horizon
Filters
Rows
Reports for KTTA — sortable, filterable
TypeNow
Sep 16, 2026
5w ago
8-K
NEUTRAL ★ 3/10
$0.5067 $0.4101▼ −19.06%▼ −20.27%$0.4000 (−21.06%)
Sep 14, 2026
6w ago
Press Release
NEUTRAL ★ 4/10
$0.5100 $0.4475▼ −12.25%▼ −14.52%$0.4000 (−21.57%)
Showing 2 of 2

US Market Status

Market Closed — Opens in 9h 29m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 16, 2026